Clinical analysis of conformal and intensity-modulated radiotherapy in patients with recurrent ovarian cancer
Open Access
- 14 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 10 (1), 1-8
- https://doi.org/10.1038/s41598-020-74356-7
Abstract
We aimed to provide evidence for radiotherapy treatment regimens in patients with clinically recurrent ovarian cancer. We analyzed the survival and prognostic factors in 43 patients who were treated for recurrent ovarian cancer at 58 tumor sites using three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) during January 2006–December 2017. t years 1, 2, and 3, overall survival (OS) rate was 82.4%, 68.4%, and 57.9%; local control (LC) rate was 100%, 100% and 80%; recurrence free survival (RFS) rate was 86.8%, 66.6%, and 61.1%; and disease-free survival (DFS) rate was 79.7%, 56.7%, and 46.8%, respectively. The radiotherapy technique was determined to be an independent prognostic factor for survival; the survival rate of patients was significantly improved with IMRT compared to 3D-CRT (P = 0.035). Radiotherapy dose was an independent prognostic factor; survival rate improved when patients were treated with a radiation dose ≥ 60 Gy as compared to < 60 Gy (P = 0.046). Elective nodal prophylactic radiation therapy (ENRT) did not lead to a significant improvement in survival when compared to involved-field radiation therapy (IFRT). The toxicities of 3D-CRT and IMRT were tolerable. One patient (2.3%) had grade 3 acute gastrointestinal (GI) toxicity, 2 (4.6%) grade 3 late GI toxicity, 5 (11.6%) grade 3 hematological toxicity, and 2 (4.6%) had grade 4 hematological toxicity. IMRT improved LC and OS in patients with recurrent ovarian cancer after surgery and multiple chemotherapy; toxicities were tolerable. The IMRT technique and radiotherapy dose of ≥ 60 Gy had independent prognostic significance for the survival of such patients.This publication has 16 references indexed in Scilit:
- Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapyGynecologic Oncology, 2016
- Weekly Paclitaxel versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III StudyClinical Medicine Insights: Oncology, 2016
- Involved-field radiation therapy for locoregionally recurrent ovarian cancerGynecologic Oncology, 2013
- Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapyJournal of Radiation Research, 2012
- Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective studyBMC Cancer, 2011
- Intraoperative Electron Beam Radiotherapy (IOERT) in the Management of Recurrent Ovarian MalignanciesInternational Journal of Gynecologic Cancer, 2011
- Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III - The OVAR-IMRT-02 StudyBMC Cancer, 2011
- Intraoperative radiation therapy in recurrent ovarian cancerEndocrine, 2005
- Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancerGynecologic Oncology, 2005
- Selective Irradiation for the Treatment of Recurrent Ovarian Carcinoma Involving the Vagina or RectumGynecologic Oncology, 2001